🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Intracavernosal administration of autologous ADRC

    The First People's Hospital of Lianyungang

    Erectile Dysfunction

    phase 2 other completed

    1 trial

  2. Intranasal Oxytocin

    United Therapeutics Europe Ltd

    Autism Spectrum Disorder

    phase 2 small molecule completed

    1 trial

  3. Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastasis of HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  4. Intravenous esketamine using Dixon's up-and-down sequential method

    The First People's Hospital of Lianyungang

    Hepatic Neoplasm

    phase 2 small molecule active

    1 trial

  5. Intraventricular Pemetrexed

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Leptomeningeal Metastasis

    phase 2 small molecule active

    1 trial

  6. Intravitreal injection of KH902

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neovascular Age-related Macular Degeneration

    phase 2 mab completed

    1 trial

  7. Iparomlimab and Tuvonralimab Injection (QL1706)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  8. Iparomlimab and Tuvonralimab Injection (QL1706)

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  9. Iparomlimab and Tuvonralimab Injection in combination with TFOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  10. Iparomlimab and Tuvonralimab combined with lenvatinib and SOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. Iparomlimab/Tuvonralimab

    The First People's Hospital of Lianyungang

    Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  12. Irinotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. Irinotecan Liposome

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  14. Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  15. Ivonescimab 20 mg/kg

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  16. Ivonescimab Combined With Chemotherapy

    The First People's Hospital of Lianyungang

    Pretreated Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  17. Ivonescimab combined with TP

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  18. Ivosidenib combined with venetoclax and azacitidine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  19. Ivosidenib, Venetoclax, Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML

    phase 2 small molecule active

    1 trial

  20. JDB0131

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Drug-resistant Tuberculosis

    phase 2 small molecule active

    1 trial

  21. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    MMRd/MSI-H stage II-III endometrial cancer

    phase 2 small molecule active

    1 trial

  22. JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Cervical cancer

    phase 2 small molecule active

    1 trial

  23. JNJ-68284528, CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusion

    Janssen-Cilag International N.V.

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  24. JNT-517 Suspension

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources